EAST HANOVER, N.J., Dec. 8, 2020 /PRNewswire/ — Detailed results from the Phase III ASCEMBL study demonstrate that, at 24 weeks, asciminib (ABL001)…

Home »
EAST HANOVER, N.J., Dec. 8, 2020 /PRNewswire/ — Detailed results from the Phase III ASCEMBL study demonstrate that, at 24 weeks, asciminib (ABL001)…
The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against COVID-19. In a new study published in mBio, an…